1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

Price 'Not Aware' Of Stock Choices During HIP Act Consideration, He Tells Senators

 
• By Sue Darcey

HHS Secretary Nominee Rep. Tom Price, R-Ga., told members of a key Senate health panel that he was "not aware" of purchases his broker made of stocks in health-care companies including Zimmer Biomet Holdings Inc., shortly after introducing The HIP Act to delay a CMS orthopedics bundled payment program. The appointee also signaled his intentions 'not to pull the rug out' on millions of Americans' insurance coverage in any Affordable Care Act replacement plan he works on.

Several Democratic Senators including Patty Murray of Washington, Al Franken of Minnesota, and Elizabeth Warren of Massachusetts berated HHS Secretary Nominee Rep. Tom Price, R-Ga., Jan. 18 for investing more than $300,000 of health care stocks simultaneous to his work on prominent pieces of health-care legislation, saying that the appearance of conflicts-of-interest alone made him unfit to take on his new role.

They and other democratic members of the Senate Health, Education, Labor and Pensions Committee on Jan. 18 grilled the nominee...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

Final Curtain For LDTs? FDA Will Not Appeal District Court Decision To Vacate Final Rule

 
• By Brian Bossetta

The US FDA has given up on its effort to regulate lab-developed tests as medical devices, at least for now. The agency will not appeal a decision from the Eastern District of Texas that tossed out the FDA’s final rule, leaving the agency with few cards.

Industry Execs Talk Tariff Turbulence During MD&M East

 
• By Brian Bossetta

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

Debate On FDA User Fee Reauthorization Begins To Take Shape

 
• By Elizabeth Orr

A battle may be forming over the 2027 FDA user fee reauthorizations. At a conference Friday, Democratic Rep. Jake Auchincloss supports them for their effectiveness, while Deputy FDA Commissioner Grace Graham echoed criticisms from HHS Sec. Kennedy, among others, in calling for reform to ensure public trust.

Health Secretary Defends Spending Cuts During Senate Hearing On HHS Budget

 
• By Elizabeth Orr

Health and Human Services Secretary Robert F. Kennedy Jr. emphasized administrative cost reductions and defended budget decisions during a Senate hearing on HHS funding. Some senators, however, expressed concerns over the impacts spending cuts had on essential health programs.

More from Policy & Regulation

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By Elizabeth Orr

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

MHRA’s Tallon Hails PMS Regulation As Start Of UK Device Framework Transformation

 
• By Ashley Yeo

16 June marked the first major new regulatory instrument in the UK’s post-Brexit transition to a standalone device regulatory system for Great Britain.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By Elizabeth Orr

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.